Login
Search Button
Button
Home
My NEI
CNS Spectrums
Store
About NEI
Search
Create Account
Search
View Cart
(0)
Log In
Membership
Membership Information
Sign Up or Renew
Overview
Rates
Groups and Institutions
Download Brochure
Member Benefits
Patient Education
Master Psychopharmacology Program
Stahl's Essential Psychopharmacology, Video Edition
Encore Presentations
NEI Prescribe
Become a Member
My NEI Portal
Meetings
NEI Meetings
Congress
Synapse
Saturday Morning Live
Practice Tools
Practice Tools
NEI Prescribe (Web Access)
NEI Prescribe (Download App)
Prescriber's Guide (PDFs)
Medication Tips and Pearls
Patient Education
Teaching Tools
Teaching Tools
Teaching Videos
Stahl's Essential Teaching Slides and Tests
NEI Teaching Slides
Proctor: Master Psychopharmacology Program
Online CME/CE
By Format
Featured Activities
On Demand Videos
Cases
Articles
Animations
Self-Assessments (MOC)
Certificate Program
By Specialty
Primary Care
Pediatric
My NEI
June is Pride Month
June 1, 2023
June is Pride Month and it’s important to understand the barriers to mental health treatment the impact the LGBTQ+ community...
Continue reading
World Schizophrenia Day: Education and Tool for Providers
May 24, 2023
The high rates of treatment resistance, relapse rates, and incidence of adverse effects in patients with schizophrenia suggest that a major treatment gap continues to still exist. Education is an essential tool in order for clinicians to integrate the new data, treatment options, and recommended management strategies into clinical practice as they become available...
Continue reading
Role of the Gut-Brain Axis and Psychiatric Diseases
May 15, 2023
Numerous studies have found a profound association between gastrointestinal and psychiatric illnesses, likely mediated by the gut-brain axis. In this extensive study, Gong and colleagues used a myriad of genetic association techniques to reveal genetic factors that may influence the correlation of gastrointestinal and psychiatric disorders. Specifically, the authors investigated genome-wide pleitropic associations between gastrointestinal tract diseases ..
Continue reading
(Members only)
Severe Depression Linked to Physical Illness
May 12, 2023
A recent study investigated the most common causes of hospitalization due to physical conditions among people with depression. Data from a prospective, population-based cohort in the United Kingdom were used for primary analyses. Replication analyses included data from two ....
Continue reading
(Members only)
FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia
May 10, 2023
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application of brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia (AAD). This is the first FDA-approved treatment indicated for AAD in the United States...
Continue reading
Ketamine for Treatment Resistant Depression with Comorbid Borderline Personality Disorder
May 9, 2023
Individuals with borderline personality disorder (BPD) are likely to suffer from major depressive disorder (MDD) with rates ranging from 71% to 83%. Comorbid presentation of BPD and MDD can result in earlier onset of MDD, more severe depression, greater treatment resistance, and more severe functional impairment. Perhaps most important, patients with comorbid BPD and MDD are twice as likely to be associated with poor response to treatment for depression compared to those without comorbid BPD...
Continue reading
(Members only)
New Tool Accurately Predicts Suicide Risk in Serious Mental Illness
May 7, 2023
Arguably the worst outcome in mental illness is death by suicide, and one of the greatest challenges in the mental heath care field is accurately determining which patients are at high risk of suicide so that intervening measures can be implemented. The Oxford Mental Illness and Suicide Tool (OxMIS) is a risk assessment tool designed to measure suicide risk in patients with severe mental illness...
Continue reading
(Members only)
Tardive Dyskinesia Awareness Week
May 3, 2023
Every year, we recognize the first full week of May as Tardive Dyskinesia Awareness Week (TDAW), to help increase awareness and education about tardive dyskinesia. This includes awareness to health care providers around the importance of regular screening for tardive dyskinesia, and effectively treating this condition. An estimated 600,000 people in the United States have tardive dyskinesia, and that number is expected to...
Continue reading
Long-Term Safety of Methylphenidate in Children and Adolescents with ADHD
April 29, 2023
Methylphenidate (MPH) is the most frequently prescribed treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents; however, data on long-term safety are limited. A naturalistic, longitudinal, controlled, multi-site study assessed the safety of MPH over 2 years in participants aged 6–17 years old....
Continue reading
(Members only)
FDA Approves Slow-Release Long-Acting Injectable of Risperidone
April 28, 2023
The U.S. Food and Drug Administration has approved extended-release injectable suspension of risperidone for the treatment of schizophrenia in adults...
Continue reading
1
2
3
4
5
6
7
8
9
10
...
Top of Page
Categories
All
Addiction/Reward
Additional Neurology Topics
ADHD
Alzheimer's/Other Dementias
Anxiety/Stress-Related Disorders
Basic Neuroscience
Bipolar Disorders
Brain Injuries
Child Psychiatry
Cognitive Disorders
Eating Disorders
Forensic Psychiatry
Geriatric Psychiatry
OCD
Pain
Personality Disorders
Pregnancy/Postpartum
Professional Improvement
Psychotic Disorders
Sexual Disorder
Side Effects
Sleep
Unipolar Depression